Biomm
Blood & Organ Banks · Brazil · 51-200 Employees
View Company Info for Free
Overview
Headquarters
705 Avenida Regent, Nova Lima, Minas Ger...Phone Number
+55 3132991000Website
www.biomm.comRevenue
$20 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
3
1
2
About Biomm
Biomm is a pioneering biotechnology company in Brazil that develops innovative biopharmaceuticals aimed at transforming lives and advancing science. The company focuses on providing health solutions for individuals with chronic diseases, enhancing their access to high-tech treatments. Biomm is committed to increasing Brazil's autonomy in the pharmaceutical industry and has recently expanded its product offerings to include biosimilars for ophthalmology and cancer treatments. As a 100% national company, Biomm adheres to high governance standards and is listed on the BM&F-BOVESPA.Explore more
Biomm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biomm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Biomm, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Biomm launches new products
Funding: Get notified immidiatlly once Biomm has new funding data
Congratulate Masked Content for being promoted to Masked Content at Biomm
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Biomm is spiking on competitors!
Earning: See what the market has to say on Biomm recently announced quarterly report
Click to see if Biomm had a recent Job posting/layoffs
Check if Biomm has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Biomm is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Biomm is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Biomm.
Biomm Tech Stack
A closer look at the technologies used by Biomm
Biomm News & Media
Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days
VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that its Brazilian distribution partner, Biomm S.A. (BVMF: BIOM3), plans to submit an authorization request to the Brazilian National Health Surveillance Agency (“ANVISA”) in the next few days to conduct two Phase 3 cliniCytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications
VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Biomm S.A. in Brazil. This commercial agreement will enable Biomm to sell leronlimab in Brazil following regulatory clearance.Bio-Thera Solutions Partners with Biomm to Market BAT1706 in Brazil
GUANGZHOU, China & SAO PAULO--(BUSINESS WIRE)-- #biosimilar--Bio-Thera Solutions announces partnership with Biomm to commercialize BAT1706, a proposed bevacizumab biosimilar, in Brazil.Afrezza® (insulin human) Inhalation Powder Approved in Brazil
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Biomm
Sign Up For FreeTo access detailed company insights
Biomm is a pioneering biotechnology company in Brazil that develops innovative biopharmaceuticals aimed at transforming lives and advancing science. The company focuses on providing health solutions for individuals with chronic diseases, enhancing their access to high-tech treatments. Biomm is committed to increasing Brazil's autonomy in the pharma... Read More
